CureVac

DGAP-News: CureVac Streamlines European Network for mRNA Product Manufacturing

Retrieved on: 
Tuesday, September 14, 2021
European Medicines Agency, GSK, Novartis, Vaccination, Technology, Protein, Nasdaq, EMA, Clinical trial, Contract, CureVac COVID-19 vaccine, Infection, Vaccine, CureVac, Degenerative disease, CVAC, COVID-19, RNA, RNA transfection, Celone/San Nicola d'Arpi Airfield, Lease, Pharmaceutical industry

As a result, the existing contracts with WACKER for the manufacturing of the mRNA drug substance of CVnCoV and Celonic for the manufacturing and formulation of the mRNA drug substance of CVnCoV will be terminated.

Key Points: 
  • As a result, the existing contracts with WACKER for the manufacturing of the mRNA drug substance of CVnCoV and Celonic for the manufacturing and formulation of the mRNA drug substance of CVnCoV will be terminated.
  • CureVac's existing agreements with Rentschler Biopharma and Novartis for mRNA production and formulation are unaffected by this adjustment and remain in place.
  • CureVac first announced the build-up of its broad external European manufacturing network in November 2020, next to the ongoing expansion of large in-house clinical and commercial manufacturing capacities.
  • Since then, several manufacturing agreements were made with highly experienced Contract Development and Manufacturing Organization partners for each of the key manufacturing steps for CVnCoV.

US and EU Biotech Industry VC Investment Report 2021 with Focus on CGT - ResearchAndMarkets.com

Retrieved on: 
Monday, September 13, 2021
Biotechnology, Pharmaceutical, Health, CGT, Industry, Investment, VC, CureVac, Biotechnology, Renewable energy, Professional services, Fine chemical, Pet

The "US and EU Biotech Industry VC Investment Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US and EU Biotech Industry VC Investment Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This report reviews the significant drivers that will propel the VC investment in biotech and specifically CGT.
  • Other discussions on the biotech VC investment trend include:
    The healthcare sector VC landscape in the US and EU from 2018 to 2020.
  • Analysis of global biotech VC deals by stage of clinical development from 2016 to H1 2021.

Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

Retrieved on: 
Wednesday, September 8, 2021
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in Citi's 16th Annual BioPharma Virtual Conference 2021 investor conference.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in Citi's 16th Annual BioPharma Virtual Conference 2021 investor conference.
  • Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (230 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Retrieved on: 
Tuesday, September 7, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Genetics, Clinical Trials

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor and scientific conferences.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor and scientific conferences.
  • Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (230 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).

DGAP-News: CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet

Retrieved on: 
Tuesday, August 31, 2021
Population, EMA, Infection, SM-102, Protein, CureVac COVID-19 vaccine, Hospital, European Medicines Agency, CVAC, Nasdaq, RNA, Disease, Death, CureVac, RNA transfection, Patient, Vaccine, LNP, GSK, COVID-19, Technology, Degenerative disease, Pharmaceutical industry, CVnCoV, CureVac, CVNCOV, CUREVAC

As previously announced, the data were based on 228 adjudicated COVID-19 cases, occurring at least two weeks after administration of the second dose.

Key Points: 
  • As previously announced, the data were based on 228 adjudicated COVID-19 cases, occurring at least two weeks after administration of the second dose.
  • CVnCoV demonstrated overall vaccine efficacy of 48% against COVID-19 disease of any severity, including single non-respiratory mild symptoms.
  • Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively.
  • A pivotal Phase 2b/3, the HERALD study, with a 12g dose of CVnCoV was initiated in December 2020.

DGAP-News: CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

Retrieved on: 
Monday, August 30, 2021
Translation, Liver, Cirrhosis, Death, Fibrosis, Infection, Therapy, Cancer, Department, Protein, Endocrinology, CVAC, Research, Nasdaq, RNA, Disease, Liver failure, HNF4A, CureVac, Antibody, RNA transfection, Liver injury, Hannover Medical School, HIV disease progression rates, European Association for the Study of the Liver, HNF4, GSK, COVID-19, Technology, Injection, Degenerative disease, Vaccine

TBINGEN, Germany/ BOSTON, USA - August 30, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the publication entitled "Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model" in the peer-reviewed Journal of Hepatology .

Key Points: 
  • TBINGEN, Germany/ BOSTON, USA - August 30, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the publication entitled "Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model" in the peer-reviewed Journal of Hepatology .
  • It provides the first preclinical data demonstrating the therapeutic applicability of mRNA-encoded HNF4A (hepatocyte nuclear factor 4 alpha) transcription factor in the treatment of liver fibrosis and cirrhosis.
  • Liver fibrosis is characterized by the formation of scar tissue in the liver, causing gradual impairment of liver function.
  • "The results of our study provide the first direct preclinical evidence that HNF4A mRNA therapeutics have the potential to treat liver fibrosis.

DGAP-News: CureVac : Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

Retrieved on: 
Tuesday, August 17, 2021
Memory B cell, Interest, Severe acute respiratory syndrome coronavirus 2, SM-102, Technology, Protein, CureVac COVID-19 vaccine, BioRxiv, CVAC, Nasdaq, RNA, Primate, Vaccine, Animal, Antibody, Alpha, Clinical trial, RNA transfection, Infection, Variant, Manuscript, Head, Partnership, LNP, GSK, Kappa, COVID-19, Degenerative disease, Pharmaceutical industry, CV2CoV, CureVac, CV2COV, CUREVAC

CureVac : Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

Key Points: 
  • CureVac : Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
    The issuer is solely responsible for the content of this announcement.
  • The study assessed cynomolgus macaques vaccinated with 12g of either the first or second-generation vaccine candidate.
  • Higher antibody neutralizing capacity was observed with CV2CoV across all selected variants, including the Beta, Delta and Lambda variants.
  • The strong immune response and protection in pre-clinical testing of this second-generation mRNA backbone are very encouraging and represent an important milestone for its further development."

Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress

Retrieved on: 
Monday, August 9, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Patent, Vaccine, COVID-19 vaccine, Cystic Fibrosis Foundation, Private Securities Litigation Reform Act, Diversified Specialty Institute Holdings, Inc., Janssen Pharmaceuticals, Duke–NUS Medical School, COVID-19, ARCT, Glycogen storage disease, Messenger RNA, Cystic fibrosis, Gene editing, Nasdaq, Takeda Pharmaceutical Company, RNA transfection, DNA, NASH, Severe acute respiratory syndrome coronavirus 2, OTC, Hepatitis B virus, SEC, LinkedIn, ARCT-021, Risk, Fatty liver disease, Intention, Safety, RNA, Therapy, MicroRNA, CureVac, Johnson & Johnson, Twitter, Annual report, Company, Pharmaceutical industry

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (229 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.
  • All other trademarks, services marks, and trade names in this announcement are the property of their respective owners.

DGAP-News: CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60

Retrieved on: 
Wednesday, June 30, 2021
Clinical trials, COVID-19 vaccines, RNA vaccines, Medicine, Health, Medical specialties, Vaccination, Medical research, COVID-19 vaccine, CureVac, Vaccine, CVnCoV, CureVac, CVNCOV, CUREVAC

CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60

Key Points: 
  • CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60
    The issuer is solely responsible for the content of this announcement.
  • In the same age group, CVnCoV provided 100% protection (vaccine 0 vs. 6 placebo) against hospitalization or death.
  • In participants above 60 years, who represented 9% of the analysed cases, the available data did not enable a statistically significant determination of efficacy.
  • In the age group of 18 to 60, across strains of higher prevalence, strain-dependent vaccine efficacy ranged from approximately 42% to up to 67%.

DGAP-News: CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)

Retrieved on: 
Wednesday, June 30, 2021
CureVac, Tübingen, Pharmaceutical companies, Gerd Greune, Health care

CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mlbe to Lead Accelerated Development of The RNA Printer(R)

Key Points: 
  • CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mlbe to Lead Accelerated Development of The RNA Printer(R)
    The issuer is solely responsible for the content of this announcement.
  • Dr. Greune joins CureVac with extensive experience in the global pharmaceutical industry, including manufacturing of vaccines and fill & finish of biologics.
  • "On behalf of the Supervisory Board I would like to welcome Dr. Greune to the Management Board.
  • "I would like to thank Dr. von der Mlbe for his service on the CureVac Management Board.